Bio-Works Technologies (BIOWKS) Q3 2025 earnings summary

Executive summary

• Net sales increased by 70% year-over-year to 16.6 MSEK in Q3 2025, with strong growth in Europe and North America.

• Operating loss narrowed to -1.2 MSEK from -5.1 MSEK in Q3 2024, reflecting higher sales and controlled costs.

• Order intake rose to 10.0 MSEK in Q3, up from 3.1 MSEK, and the order book remains solid entering Q4.

• Production capacity was doubled, eliminating bottlenecks and supporting future growth.

Financial highlights

• Q3 net sales: 16.6 MSEK (9.8 MSEK in Q3 2024); YTD net sales: 38.8 MSEK (22.8 MSEK in 2024).

• Q3 operating profit: -1.2 MSEK (-5.1 MSEK in Q3 2024); YTD: -16.6 MSEK (-24.2 MSEK in 2024).

• Q3 profit: -1.4 MSEK (-5.3 MSEK in Q3 2024); YTD: -16.6 MSEK (-24.2 MSEK in 2024).

• Cash flow from operating activities Q3: -7.1 MSEK (-6.6 MSEK); YTD: -14.6 MSEK (-29.3 MSEK).

• Cash and cash equivalents at period end: 21.5 MSEK (47.9 MSEK in 2024).

• Earnings per share Q3: -0.02 SEK (-0.12 SEK); YTD: -0.21 SEK (-0.60 SEK).

Outlook and guidance

• Focus remains on profitability, stable operating expenditure, and further improvement in margins.

• Entering Q4 with a strong order book and growing customer base.

• Operations are financed for at least the next 12 months.